Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes

    ... our studies identify severe baseline neutropenia as a risk factor for infection-associated adverse events after induction chemotherapy and ... the rationale for the risk-adapted testing of myeloid growth factor support in this high-risk AML/MDS patient subset. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. The Evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.

    ... chain reaction was used to determine the gene expression of growth differentiation factor 15 and twisted gastrulation 1. Serum ferritin (SF), C-reactive ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... downstream of EPO action. Novel transforming growth factor (TGF)-β superfamily inhibitors sotatercept and luspatercept ...

    Research Article last updated 10/23/2017 - 11:08am.

  7. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... downstream of EPO action. Novel transforming growth factor (TGF)-β superfamily inhibitors sotatercept and luspatercept ...

    Research Article last updated 10/02/2017 - 10:10am.

  8. Immunosuppressive Therapy

    ... in about 7 out of 10 cases. When a platelet growth factor called eltrombopag (Promacta®) is also given, more than 7 ...

    Topic section last updated 07/06/2018 - 11:17am.

  9. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise ...

    Research Article last updated 09/18/2017 - 1:38pm.

  10. Promising trial results for lower-risk MDS drug

    ... is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise ...

    Article last updated 09/07/2017 - 11:08am.